EGFR and non-small cell lung carcinoma: For example, a retrospective review published in 2018 included 145 patients with oligometastatic EGFR-mutant NSCLC divided into three groups: (1) 51 patients with consolidative local ablative therapy to all oligometastatic sites, (2) 55 patients with consolidative local ablative therapy to either primary tumor or oligometastatic sites, and (3) 39 patients who did not receive local therapy [33].